# Minocycline Treatment Improves Memory and Reduces Anxiety by Lowering Levels of Brain Amyloid Precursor Protein and Indoleamine 2,3-Dioxygenase in a Rat Model of Streptozotocin-Induced Alzheimer’s Disease

**Authors:** Grzegorz Świątek, Jowita Nowakowska-Gołacka, Monika Słomińska-Wojewódzka, Wojciech Glac, Oliwia Harackiewicz, Ewelina Kurowska-Rucińska, Danuta Wrona

PMC · DOI: 10.3390/ijms26199397 · 2025-09-26

## TL;DR

Minocycline improves memory and reduces anxiety in a rat model of Alzheimer's disease by lowering brain proteins linked to the disease and reducing inflammation.

## Contribution

The study demonstrates minocycline's novel neuroprotective and psychotropic effects in an Alzheimer's model via APP and IDO1 modulation.

## Key findings

- Minocycline improved memory and reduced anxiety in rats with Alzheimer's disease.
- Treatment reduced amyloid precursor protein and IDO1 levels in brain regions.
- Minocycline induced an anti-inflammatory response in the blood.

## Abstract

Minocycline (MINO), a classic antibiotic, may have psychotropic activity related to the modulation of the tryptophan-kynurenine pathway. In this study, we investigated the effects of MINO on (1) memory and anxiety behaviors, (2) the modulation of brain levels of amyloid precursor protein (APP) and 2,3-indoleamine dioxygenase (IDO1) levels, and (3) peripheral inflammatory markers in a streptozotocin (STZ)-induced rat model of sporadic Alzheimer’s disease (sAD). After repeated treatment with a dose of 35 mg/kg MINO for seven consecutive days, male Wistar rats with sAD showed (1) improvements in early (29 days after injection, probe test) reference memory (decreased latency to reach the platform, increased time in the critical quadrant of the Morris water maze) and anxiety disorders (increased time in the open arms of the elevated plus maze; increased exploration and entrances in the center of the white–light illuminated open field) 45–46 and 90–91 days after STZ injection; (2) reduced APP and IDO1 levels in the hippocampus and prefrontal cortex; and (3) induction of anti-inflammatory response in blood (increased TCD4+ lymphocyte number and interleukin-10 production). This suggests that MINO, due to its anti-inflammatory action, improves memory and anxiety behavior related to sAD, indicating its neuroprotective and psychotropic properties.

## Linked entities

- **Proteins:** IDO1 (indoleamine 2,3-dioxygenase 1)
- **Chemicals:** minocycline (PubChem CID 54675783), streptozotocin (PubChem CID 29327)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** Il10 (interleukin 10) [NCBI Gene 25325] {aka IL10X, If2a}, App (amyloid beta precursor protein) [NCBI Gene 54226] {aka Abeta}, Ido1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 66029] {aka Ido, Indo}
- **Diseases:** inflammatory (MESH:D007249), anxiety disorders (MESH:D001008), Alzheimer's Disease (MESH:D000544), Anxiety (MESH:D001007)
- **Chemicals:** STZ (MESH:D013311), kynurenine (MESH:D007737), MINO (MESH:D008911), tryptophan (MESH:D014364)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12524683/full.md

---
Source: https://tomesphere.com/paper/PMC12524683